Drugs Affecting Blood and Blood Formation — MCQs

An 18-year-old previously healthy man is placed on intravenous heparin after having a pulmonary embolism (PE) after exploratory laparotomy for a small-bowel injury following a motor vehicle collision. Five days later, his platelet count is 90,000/mL and continues to fall over the next several days. The patient's serum is positive for antibodies to the heparin-platelet factor complexes. Which of the following is the most appropriate next management step?

Q218Easy

Heparin therapy should be monitored with intermittent estimation of which of the following?

Q219Medium

Which anticoagulant is only effective in vivo?

Q220Easy

Apixaban is:

Drugs Affecting Blood and Blood Formation Indian Medical PG Practice Questions and MCQs

Question 211: Caplacizumab is used for the treatment of which condition?

A. Acquired Thrombotic Thrombocytopenic Purpura (aTTP) (Correct Answer)
B. Plaque Psoriasis
C. Breast cancer
D. Bladder cancer

Explanation: **Explanation:** **Caplacizumab** is a novel, humanized **bivalent nanobody** (a single-variable-domain antibody fragment) specifically designed to target the A1 domain of **von Willebrand factor (vWF)**. 1. **Why Option A is correct:** Acquired Thrombotic Thrombocytopenic Purpura (aTTP) is caused by a deficiency of the ADAMTS13 enzyme, leading to ultra-large vWF multimers. These multimers cause spontaneous platelet aggregation and microvascular thrombosis. Caplacizumab **inhibits the interaction between vWF and the platelet glycoprotein Ib-IX-V receptor**, thereby preventing the formation of microthrombi and the subsequent consumption of platelets. It is used as an adjunct to plasma exchange and immunosuppressive therapy. 2. **Why other options are incorrect:** * **Plaque Psoriasis:** Treated with biologics targeting IL-17 (Secukinumab), IL-23 (Ustekinumab), or TNF-alpha (Adalimumab). * **Breast Cancer:** Common targeted therapies include Trastuzumab (anti-HER2) or Palbociclib (CDK4/6 inhibitor). * **Bladder Cancer:** Often treated with Pembrolizumab (PD-1 inhibitor) or Enfortumab vedotin (Nectin-4 inhibitor). **High-Yield Clinical Pearls for NEET-PG:** * **Mechanism:** Anti-vWF nanobody (prevents platelet adhesion). * **Indication:** First-line treatment for **aTTP** to achieve faster platelet normalization and reduce recurrence. * **Route:** Administered intravenously (loading dose) followed by subcutaneous injections. * **Adverse Effect:** Increased risk of **bleeding** (epistaxis, gingival bleeding) due to its mechanism of preventing platelet-vWF binding.

Question 212: Which of the following is an antifibrinolytic drug?

A. Tenecteplase
B. Heparin
C. Urokinase
D. Tranexamic acid (Correct Answer)

Explanation: **Explanation** The correct answer is **D. Tranexamic acid.** **1. Why Tranexamic Acid is Correct:** Tranexamic acid is a synthetic derivative of the amino acid lysine. It acts as an **antifibrinolytic** by competitively inhibiting the activation of plasminogen to plasmin. It binds to the lysine-binding sites on plasminogen molecules, preventing them from binding to fibrin. This stabilizes the fibrin clot and prevents its degradation (fibrinolysis). It is clinically used to reduce bleeding in conditions like menorrhagia, post-prostatectomy, and trauma (CRASH-2 trial). **2. Why Other Options are Incorrect:** * **A. Tenecteplase:** This is a third-generation **thrombolytic** (fibrinolytic) agent. It is a genetically engineered variant of tissue plasminogen activator (t-PA) with a longer half-life and higher fibrin specificity, used in the management of acute myocardial infarction. * **B. Heparin:** This is an **anticoagulant**. It acts by activating Antithrombin III, which then inactivates Thrombin (Factor IIa) and Factor Xa. It prevents the *formation* of a clot but does not dissolve existing clots or inhibit fibrinolysis. * **C. Urokinase:** This is a **thrombolytic** enzyme produced naturally by the kidneys. It directly converts plasminogen to plasmin, thereby promoting the breakdown of fibrin clots. **3. High-Yield NEET-PG Pearls:** * **Epsilon-aminocaproic acid (EACA)** is another lysine analogue antifibrinolytic similar to Tranexamic acid. * **Aprotinin** is a direct plasmin inhibitor (also inhibits kallikrein) used to reduce blood loss during cardiac surgery. * **Side Effect:** A rare but high-yield side effect of Tranexamic acid is **color vision disturbances** (chromatopsia). * **Antidote:** Tranexamic acid can be used as an "antidote" for bleeding caused by thrombolytic overdose.

Question 213: Which of the following is a Protein C analogue?

A. Eltrombopag
B. Drotrecogin alfa (Correct Answer)
C. Andexanat alfa
D. Idarucizumab

Explanation: **Explanation:** **Correct Answer: B. Drotrecogin alfa** Drotrecogin alfa is a **recombinant form of human Activated Protein C (APC)**. In the body, Protein C is a natural anticoagulant that is activated by the thrombin-thrombomodulin complex. Once activated, it inactivates Factors Va and VIIIa, thereby limiting thrombin generation. Additionally, it possesses anti-inflammatory and profibrinolytic properties. It was historically used in the management of severe sepsis with multi-organ failure, though its clinical use has significantly declined due to concerns regarding efficacy and bleeding risks. **Analysis of Incorrect Options:** * **A. Eltrombopag:** This is an orally active **Thrombopoietin (TPO) receptor agonist**. It stimulates the proliferation and differentiation of megakaryocytes to increase platelet counts. It is used in Chronic ITP and Aplastic Anemia. * **C. Andexanet alfa:** This is a recombinant modified human **Factor Xa decoy protein**. It acts as a specific **reversal agent (antidote)** for Factor Xa inhibitors like Rivaroxaban and Apixaban. * **D. Idarucizumab:** This is a humanized monoclonal antibody fragment (Fab) that acts as a specific **reversal agent (antidote) for Dabigatran** (a direct thrombin inhibitor). **High-Yield NEET-PG Pearls:** * **Protein S** acts as a cofactor for Protein C; deficiency of either leads to a hypercoagulable state (thrombophilia). * **Warfarin-induced skin necrosis** occurs due to a rapid decline in Protein C levels (which has a short half-life) before the depletion of clotting factors. * **Romiplostim** is another TPO receptor agonist but is administered subcutaneously (unlike Eltrombopag).

Question 214: What is the formula for parenteral iron therapy?

A. 4.4 x body weight (kg) x Hb deficit (g/dL) (Correct Answer)
B. 3.3 x body weight (kg) x Hb deficit (g/dL)
C. 2.2 x body weight (kg) x Hb deficit (g/dL)
D. 1.1 x body weight (kg) x Hb deficit (g/dL)

Explanation: The correct formula for calculating the total dose of parenteral iron is based on the **Ganzoni Equation**. This formula ensures that the patient receives enough iron to restore hemoglobin to normal levels and replenish depleted iron stores. ### **Explanation of the Correct Answer** **Option A (4.4 x body weight x Hb deficit)** is the correct simplified version of the Ganzoni Equation. * **The Logic:** To raise hemoglobin (Hb) by 1 g/dL, approximately 150 mg of iron is needed in an average adult. When factored by body weight (kg) and the deficit (Target Hb - Actual Hb), the constant **2.4** is typically used if Hb is in g/dL. However, when accounting for **iron stores** (usually 500 mg for adults), the simplified clinical multiplier often cited in standard pharmacology textbooks (like KD Tripathi) for total replacement is **4.4**. * **Formula:** Total Iron Dose (mg) = 4.4 × Body weight (kg) × Hb deficit (g/dL). ### **Why Other Options are Incorrect** * **Options B, C, and D** (3.3, 2.2, 1.1) are mathematically incorrect. These multipliers would result in significant under-dosing, failing to provide enough elemental iron to both reach the target hemoglobin level and provide the necessary 500 mg buffer for storage (ferritin). ### **NEET-PG High-Yield Pearls** 1. **Indications for Parenteral Iron:** Oral iron intolerance (most common), malabsorption (Celiac disease), chronic kidney disease (CKD) on erythropoietin, or the need for rapid replenishment (e.g., late pregnancy). 2. **Iron Sucrose vs. Ferric Carboxymaltose:** Iron sucrose is given in divided doses, whereas Ferric Carboxymaltose can be given as a large single-dose infusion. 3. **Adverse Effects:** Anaphylaxis is a risk (highest with older High Molecular Weight Iron Dextran). Always monitor the patient for at least 30 minutes post-infusion. 4. **Target Hb:** Usually taken as 14 g/dL or 15 g/dL for calculation purposes.

Question 215: Which of the following is most useful in the treatment of Kostmann's Syndrome?

A. Sargramostim
B. Aldesleukin
C. Oprelvekin
D. Filgrastim (Correct Answer)

Explanation: **Explanation:** **Kostmann’s Syndrome** (Severe Congenital Neutropenia) is an autosomal recessive disorder characterized by a maturation arrest of neutrophil precursors in the bone marrow, leading to absolute neutrophil counts (ANC) below 200/µL and life-threatening infections. **Why Filgrastim is the Correct Answer:** **Filgrastim** is a recombinant human **Granulocyte Colony-Stimulating Factor (G-CSF)**. It specifically stimulates the proliferation and differentiation of progenitor cells into mature neutrophils and enhances their phagocytic activity [2]. It is the gold-standard treatment for Kostmann’s Syndrome, significantly increasing the ANC and reducing the frequency of febrile episodes [2]. **Analysis of Incorrect Options:** * **A. Sargramostim:** This is a recombinant **GM-CSF** (Granulocyte-Macrophage Colony-Stimulating Factor). While it stimulates neutrophils, it also affects monocytes, macrophages, and eosinophils [1]. It is less specific than Filgrastim and is typically used for myeloid recovery after bone marrow transplantation or chemotherapy [1], [2]. * **B. Aldesleukin:** This is a recombinant **Interleukin-2 (IL-2)**. It promotes the proliferation of T-lymphocytes and NK cells [2]. It is used in the treatment of metastatic renal cell carcinoma and malignant melanoma, not neutropenia. * **C. Oprelvekin:** This is a recombinant **Interleukin-11 (IL-11)**. It acts as a thrombopoietic growth factor used to prevent severe **thrombocytopenia** following myelosuppressive chemotherapy. **High-Yield Clinical Pearls for NEET-PG:** * **Filgrastim Side Effect:** The most common side effect is **bone pain** (due to marrow expansion). * **Pegfilgrastim:** A pegylated form of G-CSF with a much longer half-life, allowing for once-per-chemotherapy-cycle dosing. * **Kostmann’s Mutation:** Often associated with mutations in the **ELANE** gene (encoding neutrophil elastase) or **HAX1** gene. * **Long-term Risk:** Patients with Kostmann’s Syndrome treated with G-CSF have an increased risk of developing AML (Acute Myeloid Leukemia) or MDS.

Question 216: Which of the following is a complication of heparin?

A. Bleeding
B. Thrombocytopenia
C. Osteoporosis
D. All of the above (Correct Answer)

Explanation: **Explanation:** Heparin is a rapid-acting parenteral anticoagulant that acts by activating Antithrombin III. While highly effective, it is associated with several significant adverse effects, making **"All of the above"** the correct choice. 1. **Bleeding (Option A):** This is the most common complication of heparin therapy. It occurs due to the excessive inhibition of factors Xa and IIa (Thrombin). The risk is increased in elderly patients and those with renal failure. The specific antidote for heparin-induced bleeding is **Protamine Sulfate**. 2. **Thrombocytopenia (Option B):** Heparin-Induced Thrombocytopenia (HIT) is a serious immunologic reaction. **Type II HIT** is high-yield for exams; it is caused by IgG antibodies against the **Heparin-Platelet Factor 4 (PF4) complex**, leading to platelet activation and paradoxical thrombosis. 3. **Osteoporosis (Option C):** Long-term heparin use (typically >6 months, often during pregnancy) can lead to decreased bone density and spontaneous fractures. Heparin accelerates osteoclast activity and inhibits osteoblast formation. **Clinical Pearls for NEET-PG:** * **Monitoring:** Unfractionated Heparin (UFH) is monitored using **aPTT** (Target: 1.5–2.5 times the control). Low Molecular Weight Heparin (LMWH) usually doesn't require monitoring but can be checked using **Factor Xa assay**. * **Hyperkalemia:** Heparin can cause hypoaldosteronism by inhibiting the adrenal cortex, leading to potassium retention. * **Alopecia:** Transient hair loss is a rare, reversible side effect. * **LMWH vs. UFH:** LMWH (e.g., Enoxaparin) has a lower risk of HIT and osteoporosis compared to UFH.

Question 217: An 18-year-old previously healthy man is placed on intravenous heparin after having a pulmonary embolism (PE) after exploratory laparotomy for a small-bowel injury following a motor vehicle collision. Five days later, his platelet count is 90,000/mL and continues to fall over the next several days. The patient's serum is positive for antibodies to the heparin-platelet factor complexes. Which of the following is the most appropriate next management step?

A. Cessation of all anticoagulation therapy
B. Cessation of heparin and immediate institution of high-dose warfarin therapy
C. Cessation of heparin and institution of low-molecular-weight heparin
D. Cessation of heparin and institution of lepirudin (Correct Answer)

Explanation: ### Explanation **Concept: Heparin-Induced Thrombocytopenia (HIT) Type II** The patient presents with a classic case of **HIT Type II**, an immune-mediated reaction caused by IgG antibodies against the **Heparin-Platelet Factor 4 (PF4) complex**. This typically occurs 5–10 days after starting heparin, leading to platelet activation, consumption (thrombocytopenia), and a paradoxical high risk of arterial and venous thrombosis. **Why Option D is Correct:** The management of HIT requires the **immediate cessation of all heparin products** (including LMWH) and the initiation of a non-heparin anticoagulant. **Lepirudin** (a recombinant Hirudin) is a **Direct Thrombin Inhibitor (DTI)** that does not cross-react with HIT antibodies, making it a safe and effective alternative for systemic anticoagulation in these patients. **Why Other Options are Wrong:** * **Option A:** Stopping all anticoagulation is dangerous. HIT is a pro-thrombotic state; without alternative anticoagulation, the patient is at high risk for new or worsening PE/thrombosis. * **Option B:** Warfarin should **never** be used as monotherapy in acute HIT. It can cause a rapid drop in Protein C levels, leading to a hypercoagulable state and **venous limb gangrene**. Warfarin is only started after the platelet count has recovered to >150,000/mL. * **Option C:** LMWH (e.g., Enoxaparin) is contraindicated because it has high cross-reactivity (nearly 100%) with HIT antibodies and will worsen the condition. **NEET-PG High-Yield Pearls:** * **Gold Standard Diagnosis:** Serotonin Release Assay (SRA). * **Screening Test:** ELISA for anti-PF4 antibodies (high sensitivity, low specificity). * **Alternative DTIs:** Argatroban (safe in renal failure) and Bivalirudin. * **Lepirudin Note:** It is renally excreted; monitor APTT closely. * **HIT Type I:** A non-immunologic, transient drop in platelets occurring within 48 hours; heparin can be continued.

Question 218: Heparin therapy should be monitored with intermittent estimation of which of the following?

A. Bleeding time
B. Prothrombin time
C. Activated partial thromboplastin time (aPTT) (Correct Answer)
D. All of the above

Explanation: The correct answer is **C. Activated partial thromboplastin time (aPTT)**. **Why aPTT is the correct choice:** Unfractionated Heparin (UFH) exerts its anticoagulant effect by binding to Antithrombin III, which subsequently inactivates Thrombin (Factor IIa) and Factor Xa [3]. The **aPTT** measures the integrity of the **intrinsic and common pathways** of the coagulation cascade. Since heparin significantly prolongs the clotting time of these pathways, aPTT is the standard laboratory test used to monitor its therapeutic efficacy and ensure safety [1]. The goal is typically to maintain the aPTT at 1.5 to 2.5 times the normal control value. **Why other options are incorrect:** * **Bleeding Time (A):** This test assesses platelet function and vascular integrity, not the coagulation cascade. While heparin affects clotting, it does not significantly alter the primary hemostatic plug formed by platelets. * **Prothrombin Time (B):** PT (and its derivative, INR) is used to monitor the **extrinsic pathway**, primarily for patients on **Warfarin** therapy. While very high doses of heparin can slightly affect PT, it is not sensitive or specific enough for monitoring heparin therapy. **High-Yield Clinical Pearls for NEET-PG:** * **Low Molecular Weight Heparin (LMWH):** Unlike UFH, LMWH (e.g., Enoxaparin) does **not** require routine monitoring due to its predictable bioavailability. If monitoring is required (e.g., in renal failure or pregnancy), the **Anti-Factor Xa assay** is used [2]. * **Antidote:** The specific antidote for heparin overdose is **Protamine Sulfate** (1 mg neutralizes ~100 units of heparin). * **Side Effects:** Watch for **Heparin-Induced Thrombocytopenia (HIT)**; if it occurs, stop heparin immediately and switch to a direct thrombin inhibitor like Lepirudin or Argatroban.

Question 219: Which anticoagulant is only effective in vivo?

A. Heparin
B. Coumarin (Correct Answer)
C. EDTA
D. Sodium citrate

Explanation: **Explanation:** The correct answer is **Coumarin** (e.g., Warfarin). The distinction between *in vivo* and *in vitro* anticoagulants is a high-yield concept in pharmacology. **1. Why Coumarin is the correct answer:** Coumarins are **indirect-acting anticoagulants**. They work by inhibiting the enzyme **Vitamin K Epoxide Reductase (VKOR)**, which prevents the gamma-carboxylation of clotting factors II, VII, IX, and X in the liver. Since this process requires an active hepatic metabolic pathway, coumarins have no effect on blood already outside the body (in a test tube). They are only effective **in vivo**. **2. Why the other options are incorrect:** * **Heparin:** It acts by activating **Antithrombin III**, which directly neutralizes thrombin and factor Xa. This interaction occurs immediately upon contact with blood, making heparin effective both **in vivo and in vitro**. * **EDTA (Ethylenediaminetetraacetic acid):** It is a powerful **chelating agent** that removes calcium ions ($Ca^{2+}$) from the blood. Since calcium is essential for the coagulation cascade (Factor IV), its removal prevents clotting. It is used primarily *in vitro* for hematological tests. * **Sodium Citrate:** Similar to EDTA, it works by **chelating calcium**. It is the anticoagulant of choice for blood transfusion and coagulation studies *in vitro*. **High-Yield Clinical Pearls for NEET-PG:** * **Bridge Therapy:** Because coumarins have a delayed onset of action (due to the half-life of existing clotting factors), heparin is used "as a bridge" for immediate effect. * **Monitoring:** Heparin is monitored by **aPTT**, while Warfarin/Coumarin is monitored by **PT/INR**. * **Antidotes:** The antidote for Heparin is **Protamine sulfate**; for Warfarin, it is **Vitamin K** (slow) or **Fresh Frozen Plasma** (rapid). * **Pregnancy:** Warfarin is **teratogenic** (causes fetal warfarin syndrome), whereas Heparin is the anticoagulant of choice in pregnancy as it does not cross the placenta.

Question 220: Apixaban is:

A. Antithrombin inhibitor
B. Direct Xa inhibitor (Correct Answer)
C. Platelet activator
D. Clotting Factor XII

Explanation: **Explanation:** **Apixaban** belongs to the class of drugs known as **Direct Oral Anticoagulants (DOACs)**. Its mechanism of action involves the direct, reversible, and highly selective inhibition of **Factor Xa** (both free and clot-bound). Factor Xa is a critical component of the "common pathway" in the coagulation cascade; by inhibiting it, Apixaban prevents the conversion of prothrombin to thrombin, thereby stopping fibrin clot formation. **Analysis of Options:** * **Option A (Antithrombin inhibitor):** This is incorrect. Drugs like Heparin actually work by *activating* Antithrombin III. Apixaban acts independently of antithrombin. * **Option C (Platelet activator):** This is incorrect. Apixaban is an anticoagulant, not a pro-coagulant. Furthermore, it affects the coagulation cascade, not platelet activation (which is the target of antiplatelet drugs like Aspirin or Clopidogrel). * **Option D (Clotting Factor XII):** This is incorrect. Factor XII (Hageman factor) is involved in the intrinsic pathway. There are currently no major clinical anticoagulants targeting Factor XII used in standard practice. **High-Yield Clinical Pearls for NEET-PG:** * **Mnemonic:** Remember the **"xa"** in the name: Api**xa**ban, Rivaro**xa**ban, and Edo**xa**ban are all direct **Xa** inhibitors. * **Monitoring:** Unlike Warfarin, DOACs do not require routine PT/INR monitoring. * **Reversal Agent:** The specific antidote for Apixaban and Rivaroxaban is **Andexanet alfa**. * **Clinical Use:** Primarily used for stroke prevention in non-valvular atrial fibrillation and the treatment/prophylaxis of DVT and pulmonary embolism.

Practice by Chapter

Hematopoietic Growth Factors

Practice Questions

Iron Preparations and Management of Iron Deficiency

Practice Questions

Vitamin B12 and Folic Acid

Practice Questions

Anticoagulants: Heparins and Direct Inhibitors

Practice Questions

Oral Anticoagulants

Practice Questions

Antiplatelet Drugs

Practice Questions

Thrombolytic Agents

Practice Questions

Hemostatic Drugs

Practice Questions

Plasma Expanders

Practice Questions

Blood Transfusion and Alternatives

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free